SolidWorld GROUP

1H 2025 Results

Agenda

1 - The Group

2 - 1H 2025 Results

3 - Annex

1 • The Group

SolidWorld Group

Leading 3D Innovation Across Strategic Sectors

SolidWorld Group is a **technology group,** leader in integrating advanced 3D digital solutions across industries driving innovation in Industry, Biomedicine & Defense.

SolidWorld GROUP

SolidWorld Group is a leading technology company, driving innovation and growth across strategic sectors through more than 20 years of expertise in 3D technology & systems. Operating through a network of specialized subsidiaries, the Group focuses on three core areas: Industrial, Defense & Aerospace and Biomedical. SolidWorld Group employs 229 professionals and serves a portfolio of around 11,000 clients.

SolidWorld GROUP

Our Group in a snapshot



Our Network of Operational and Technology Hubs

The Group operates across Italy through 14 Operational Sites and 4 Technology Hubs. It also has an international branch in the Middle East, located in Dubai.

1a Treviso (Headquarter)
- Operational headquarters: ✓
- Technological Hub: ✗
- Society: **SolidWorld**

1b Resana (TV)
- Operational headquarters: ✓
- Technological hub: ✓
- Society: **Duepigreco**

1c Ponzano Veneto (TV)
- Operational headquarters : ✓
- Technological Hub: ✓
- Society: **Duepigreco, Tecnologia & Design**

1d Verona
- Operational headquarters: ✓
- Technological Hub: ✗
- Society: **SolidWorld**

2a Brescia
- Operational Headquarter: ✓
- Polo Tecnologico: ✗
- Society: **SolidWorld, Design Systems**

2b Rescaldina (MI)
- Operational Headquarter: ✓
- Technological Hub: ✗
- Society: **SolidWorld, SolidCAM Italia, Design Systems**

2c Gallarate (VA)
- Operational Headquarter: ✓
- Technological Hub: ✗
- Society: **Valore BF 3D**

3 Torino
- Operational Headquarter: ✓
- Technological Hub: ✗
- Society: **SolidWorld**

4 Genova
- Operational Headquarter: ✓
- Technological Hub: ✗
- Society: **Design Systems**

5a Bentivoglio (BO)
- Operational Headquarter: ✓
- Technological Hub: ✓
- Society: **SolidWorld, SolidCAM Italia, Energy Group, SolidInnovation**

5b Barberino Tavarnelle (PI)
- Operational Headquarter: ✓
- Technological Hub. ✓
- Society: **Bio3DModel**

6 Montevarchi (AR)
- Operational Headqurter: ✓
- Technological Hub: ✗
- Society: **SolidWorld**

7 Osimo (AN)
- Operational Headquarter: ✓
- Technological Hub: ✗
- Society: **SolidWorld**

8 Modugno (BA)
- Operational Headquarter: ✓
- Technological Hub: ✗
- Society: **SolidWorld**

9 Dubai
- Overseas Office: ✓
- Technological Hub: ✗
- Society: **SolidWorld Middle East**

Industrial Production Value

Top 10 Countries by Industrial Production Value

Source: Safeguard Global, CNCMachiNE



Global Industrial Output by Country*

Source: Eurostat European Commission



*In 2023, the total value of industrial production sold in the European Union reached €5.992 billion, marking a 1.2% decrease compared to 2022. The top six countries accounted for 72% of the total output. Source: European Commission

SolidWorld Group's Pillars

Empowering Industry and Defense through 3D Innovation

Industry 4.0/5.0

SUPPORTING THE DIGITAL TRANSFORMATION OF MANUFACTURING INDUSTRIES

3D CADCAM
Leading VAR for Dassault Systemes

3D Printing
Prototyping & production services
Leading equipment distributor

Turnkey Projects
Proprietary IP for industrial assembly line development

Defence

A STRATEGIC PROVIDER AND 3D TECHNOLOGY PARTNER TO OVER 300 ITALIAN COMPANIES IN THE AEROSPACE AND DEFENSE SECTOR

Drones
Advanced engineering, innovation and taylor-made solutions in international markets

Military means
Main supplier of important industrial players and institution

Tanks
We're specialized in technologies that speed up the industry

SolidWorld Group's Pillars

Bio3DPrinting

BREAKTHROUGH TECHNOLOGY FOR HUMAN TISSUE PRODUCTION

3D Bioprinting
University of Pisa JV's innovative machine validated by three orders for well over €1m

Bio3DModel

3D TECHNOLOGY FOR MEDICAL APPLICATIONS

Surgical Planning
Patient-specific 3D organ models to reduce clinical risk and enhance pre-operation preparation. 3D twins help surgeons rehearse complex procedures, such as tumor removals

Medical Training
3D twins of human organs allow surgical residents – significantly reducing the need for cadaver-based training.

Doctor–Patient Communication
3D models improve understanding, especially valuable in paediatrics.

Industry 4.0/5.0 – CADCAM & 3D Printing

SolidWorld Group is the leading Italian 3D digital systems integrator for manufacturers, supporting and accelerating their journey to Industry 5.0.

- 3D Scanning
- 3D Advanced Design System
- 3D Printing
- 3D Manufacturing
- 3D Printing Services
- 3D Academy

> 20
Years of Experiences in 3D Digital World

15
14 plants in Italy and 1 in UAE

Partner Products
Dassault Systèmes, Stratasys, Creaform

Own IP
Integr@, miralis

178
Group's Employees as of June 30th 2025

11,000
Clients

4
Technological hubs

Every month, a growing number of clients choose SolidWorld Group—driving consistent growth and confirming strong market momentum

Industry 4.0/5.0 – Multiple Growth Drivers

The rapid progress of manufacturing technology is creating a significant opportunity for our industrial pillar
Based in a powerhouse of European industrial production, we are in an ideal position to capitalize on trend

Modernisation of Italian Manufacturing

Italy's Piano di Transizione 5.0 setting aside **€6.3bn for digitalisation** and sustainability tax credits on investments

Acting as Consolidator in Our Industry

Italian leadership position again exploited in 2023 to acquire Valore BF3D for €2.8m, **adding 1200 customers**

Additive Manufacturing Entering Mainstream

3D-Printing services revenues now **30% actual production** vs almost 100% prototypes two years ago

Towards Subscription-Based Revenue

Shifting from a license and maintenance model to a **subscription-based model** increases recurring revenue over time.
While the license model generates a larger one-time payment initially, it provides lower ongoing income in subsequent years. In contrast, the subscription model offers consistent annual payments, leading to **higher cumulative revenue across multiple years.** This transition supports more stable and predictable financial performance, **favoring long-term growth.**

	Yr1	Yr2	Yr3	Yr4
License/Maint	100	12	12	12
Cumulative	100	112	124	136
Subscription	50	50	50	50
Cumulative	50	100	150	200

Industry 4.0/5.0 – SolidWorld Proprietary IP

Integra Suite

Developed entirely by SolidWorld Group

Enables seamless integration of:
- CAD (design software)
- PDM (product data mgmt)
- ERP (enterprise system)

By optimizing project data handling, Integr@ reduces time wasting and improves outcomes

Miralis

SolidWorld Group acquired the 22% stake of Miralis in 2024.

Miralis provides end-to-end consulting and implementation services for digital transformation projects, with a focus on PLM and business process optimization through a holistic approach.

Biomedical – Major 3D Bioprinting Innovation

Tissues printed by current 3D bioprinting offerings are limited in their applications by lack of structure

SolidWorld's highly innovative Electrospider machine solves that problem

Electrospider
3D multiscale bioprinting

Electrospider

SolidWorld Group has focused on the development of Electrospider, a **cutting-edge bioprinter** to overcome technological challenges in bioprinting related to standardization and scalability. It integrates **key innovations** across **hardware**, **software**, and **biofabrication** processes, becoming the first commercially available bioprinter that fully incorporates these features at their maximum potential.

- Combines electrospinning and extrusion techniques to deliver superior organoids and tissue samples
- Spin-off of the University of Pisa, leading Italian science athenaeum
- Worldwide patents secured in 2022



First Electrospider delivered to major Italian research hospital, and firm orders secured from companies in New Jersey and Switzerland

Biomedical – Case History

At the **Humanitas 3D Innovation Lab**, in collaboration with Politecnico di Milano and Fondazione Humanitas per la Ricerca, surgeons use advanced 3D printing and bioprinting to reproduce patient-specific organs and tissues.
The process integrates engineering, medical imaging, and Bio3DModel technology to bring precision medicine into everyday clinical practice and translational research.

Step by step:
1. Data acquisition – CT and MRI scans are converted into detailed 3D anatomical reconstructions.
2. Analysis – Mechanical data define the elasticity, resistance, and porosity of real tissues.

> **A**. 3D Printing of anatomical models (Bio3DModel) – Multi-material 3D printing is used to create patient-specific phantoms and full-scale organ replicas with realistic texture, enabling surgical simulation and pre-operative planning.
> **B.** Bioprinting of living tissues (Electrospider) – Using bioinks and cells to recreates patient-derived tissue models (e.g. tumors), providing advanced platforms for research and personalized therapeutic strategies.

3. Simulation and validation – Surgeons can test and plan complex operations on the anatomical phantoms, while researchers use bioprinted tissues to investigate disease mechanisms and treatment responses.



Link to the video: Stampare gli organi umani in 3D

Electrospider's Milestone

Sept. 2022

BIO3DModel **acquires** the **Electrospider patent** from the University of Pisa. Electrospider was presented in a world premiere at the International Conference on Biofabrication held in Montecatini Terme.

Nov. 2022

Bio3DPrinting won **first place at the Start Cup Toscana**, a regional competition that rewards the best entrepreneurial ideas coming from the research community.

Feb. 2023

Bio3DPrinting **starts mass production** of Electrospider at the company plant in Barberino Tavarnelle, just outside Florence

Apr. 2023

SolidWorld Group announces the September delivery of the first Electrospider to one of the largest and most prestigious hospitals and medical research centers in Northern Italy.

Electrospider's Milestone

Nov. 2023

Bio3DPrinting received the **"Innovation" award** at the Motore Italia Toscana Awards 2023, organized by Class Editori. The recognition was granted for the development of Electrospider, the first Italian bioprinter capable of significantly contributing to advances in regenerative medicine.

Bio3DPrinting signs an important **supply contract** for the Electrospider platform with a major **Swiss company** operating in the field of regenerative medicine, with headquarters both in Switzerland and Jersey City.

Jan. 2024

Bio3DPrinting signs an important supply contract for the Electrospider platform with a prestigious hospital institute in Lausanne, Switzerland, collaborating with the one in New York which had already issued a major order for the purchase of Electrospider in 2023.

Mar. 2024

SolidWorld Group and Humanitas University join forces to accelerate Italian medical research: Electrospider becomes one of the main technologies including the new 3DPrinting Laboratory at the Innovation Building, on the **Humanitas University campus.**

Electrospider's Milestone

May 2024

Debut at **Abu Dhabi Global Health care Week** with the presentation of Electrospider, already purchased by a local hospital.

A new patent has been filed to protect the innovative multitool printhead implemented in Electrospider.

June 2024

Implementation on Electrospider of the algorithm for the creation of vascularization of complex biological human tissues and organs, analgorithm for which the patent is being obtained.

Bio3DPrinting participated as a sponsor at the TERMIS World Congress held in Seattle.

Electrospider's Milestone

Jan 2025

Commissioning of Electrospider at the Swiss customer's site.

Feb. 2025

Presentation of Electrospider at the 3DEXPERIENCE Event held in Houston, Texas (event organized by Dassault Systèmes).

Apr. 2025

Electrospider lands in the USA: commissioning of the machine at the Jersey City customer site

Biomedical – 3D Bioprinting Market Sizing

Market researchers forecast growth to $ 5.8bn By 2030*(*Average of 7 market reports)*

The size and scope of the markets where 3D Bioprinting likely to take share or play an active part lends credence to forecasts

$1.8 bn*
2022

$5.8bn*
2030

Clinical Trials

~$50bn*
2022

Electrospider delivers a significant improvement in the quality of organoids for drug testing - likely to drive adoption in this vast market

Average of 7 mkt research firms

Animal Testing

Ethical concerns a driver for adoption

Cosmetics and Drug Testing

Bioprinting various skin types for testing

Precision Oncology

Tumour printing for therapy formulation

Vaccine Development

Bioprinting will accelerate pandemic reaction time

Organ Transplants

THE FUTURE – Our unique technology represents a major step toward the production of viable human organs for transplants

Our Strategy – Balancing our Three Pillars

We aim to take the contribution from our three areas of focus to the same order of magnitude, while continuing to grow our core business.

Here is how we plan to get there



Industry 4.0/5.0

Consolidation
Rationalisation
Turnkey Projects
Own IP sales
New 3D Printing Applications
Internationalisation
Managing of subscription migrn
Introduction of Metrology and 3D Scanner

Biomedical

Capitalise on early international successes to monetise the many ongoing conversations with research institutions interested in Electrospider

Build on Electrospider’s technological lead with Bio3Dprinting’s significant R&D effortPrototyping & production

Defense

Capitalise Monetize investments made in the technological field (Duepigreco acquisition) and relationships with major industry players

Build on 3DPrint technology and high-performance materials which allow us to offer increasingly efficient and sustainable solutions.

2. H1 2025 Financial Highlights

Consolidated Financial Highlights H1 2025

EUR 30.4 million
Revenues

EUR 31.7 million
Value of Production

EUR 0.5 million
EBITDA Adjusted

1.6%
EBITDA Adjusted %

EUR 16.6 million
Net Financial Position (Debt)

EUR -1.9 million
Net Profit

Consolidated Profit and Loss

	Income Statement (in Eur)	30.06.2025	30.06.2024
1	Revenues from sales	30.412.767	30.194.053
	Change in inventories of work-in-progress, semi-finished and finished products	(4.732)	30.359
	Increase in internal work capitalized	641.328	600.489
	Other revenues and income	643.293	6.117.826
2	**Value of production**	**31.692.656**	**36.942.727**
	Costs of raw materials, supplies and goods net of changes	(19.445.353)	(19.140.201)
	Service cost	(4.151.301)	(3.910.611)
	Rent, lease and similar costs	(1.309.883)	(1.047.764)
	expense	(5.625.084)	(5.913.226)
	Other operating expenses	(646.080)	(531.571)
3	**EBITDA**	**514.955**	**6.399.354**
	Extraordinary income	(148.386)	(124.320)
	Extraordinary charges	152.691	80.222
	EBITDA Adjusted	**519.259**	**6.355.256**
	Amrtisation depreciation and write-downs	(1.758.821)	(1.836.959)
	Provisions	(353.640)	(353.527)
	EBIT	**-1.597.506**	**4.208.868**
	Financial Results	(212.789)	112.145
	EBT	**-1.810.295**	**4.321.013**
	Income Taxes	(60.001)	(1.724.375)
4	**Profit / (Loss) for the year**	**-1.870.296**	**2.596.638**
	Group Net Profit / (Loss)	**-1.764.474**	**2.707.499**
	Minority Interest Result	**-105.822**	**-110.861**

1 **Net Revenues** from sales and services amounted to **Eur 30.4 million** . In the first half of 2025, net revenues from the Industrial division accounted for the majority of consolidated revenues, or 99.3% (99.7% as at 30 June 2024). The Biomedical pillar contributed 0.7% to consolidated revenues as of 30 June 2025 (0.3% as at 30 June 2024).

2 **Value of Production** recorded a slight decline compared to the first half of 2024 (€31.7 million compared to €36.9 million in the same period of the previous year, €31.6 million net of non-recurring items).

3 **EBITDA** amounted to €0.5 million, with an EBITDA margin of 1.6% compared to 15.6% last year.

4 The **Net profit** was €-1.9 million, compared to €2.6 million in the first half of 2024, after taxes of €0.06 million in the current half-year compared to €1.7 million in the first six months of 2024.

H1 2025 Revenue Breakdown by Industry



- Focus on industrial and defence sectors, where the integration of DuePiGreco srl and the creation of a hub dedicated to aerospace prototyping have opened up new prospects for growth and strategic partnerships at an international level. DuePiGreco's journey, accelerated by the lease of the Technology & Design business unit and the launch of the new Technology Hub in Resana, marks the start of an ambitious industrial plan based on consolidated expertise, new technologies and a results-oriented operational approach.
- In the first half of 2025, net revenues from the **Industrial** division accounted for the majority of consolidated revenues, or 99.3% (99.7% as at 30 June 2024). In particular, in the Industrial pillar:
- The **Software Sales** business line recorded consolidated revenues of €21 million, equal to 69.7% (€21.9 million, equal to 72.8% at 30 June 2024). Within this category, maintenance revenues amounted to €12.3 million (€12.5 million as of 30 June 2024), representing 58.6% of software sales revenues. The remainder mainly consists of sales and license rentals worth €5.9 million (€6.9 million in 1H24), or 28.3% of software sales revenues;
- The **Hardware Sales** line recorded revenues of €8 million, equal to 26.6% of total revenues for the first half of 2025, up 7.2% compared to the first half of 2024 (24.9%);
- **Additive Manufacturing** revenues amounted to €1.1 million, 3.7% of total revenues in the first half of 2025, up 61% compared to 2024.
- The **Biomedical** pillar contributed 0.7% to consolidated revenues as of 30 June 2025 (0.3% as of 30 June 2024).

H1 2025 Revenue Breakdown – Industrial





EBITDA, EBIT & Net Profit

	30.06.2025	30.06.2024
EBITDA Adjusted	519.259	6.355.256
Amrtisation depreciation and write-downs	(1.758.821)	(1.836.959)
Provisions	(353.640)	(353.527)
EBIT	-1.597.506	4.208.868
Financial Results	(212.789)	112.145
EBT	-1.810.295	4.321.013
Income Taxes	(60.001)	(1.724.375)
Profit / (Loss) for the year	-1.870.296	2.596.638
Group Net Profit / (Loss)	-1.764.474	2.707.499

EBITDA amounted to €0.5 million, with an EBITDA margin of 1.6% compared to 15.6% last year.

As of 30 June 2025, **Amortisation** amounted to €1.8 million, in line with €1.8 million as of 30 June 2024, attributable to increased investments in strategic sectors such as biomedical and defense.

EBIT was negative at €1.6 million (€4.2 million at 30 June 2024), after depreciation, amortisation and provisions totaling €2.1 million (€2.2 million in the same period of 2024), with an EBIT margin of -4.9% (EBIT margin of 13% in the first half of 2024).

Net profit was negative €-1.9 million, compared to €2.6 million in the first half of 2024, after taxes of €0.06 million in the current half-year compared to €1.7 million in the first six months of 2024.

Consolidated Balance Sheet

Balance Sheet (Eur)	30/06/2025	31/12/2024
Intangible assets	13.498.791	13.536.383
Tangible assets	9.945.874	9.885.562
Financial Assets	2.139.227	1.740.807
Total Assets	**25.583.892**	**25.162.752**
Inventories	3.406.226	3.395.022
Trade Receivables	21.240.664	24.054.365
Trade Payables	(11.294.601)	(15.906.963)
Commercial Working Capital	**13.352.289**	**11.542.424**
Other current assets	1.722.784	3.682.617
Other current liabilities	(5.165.973)	(8.856.293)
Tax receivables and payables	(437.566)	(275.124)
Net acrual and deferrals	(731.949)	124.101
Net Working Capital	**8.739.586**	**6.217.725**
Provisions for risk and charges	(1.151.963)	(804.463)
Post-employement benefits	(2.469.784)	(2.346.232)
Net Capital Employed (uses)	**30.701.731**	**28.229.782**
Current portion of non-current financial debt	3.694.935	2.071.746
Current financial payables	11.443.383	11.935.454
Non-current financial payables	4.248.747	4.137.251
Total Bank and financial payables	19.387.066	18.144.450
Other current financial assets	(249.609)	(312.120)
Cash	(2.492.859)	(3.241.289)
Net financial debt	**16.644.598**	**14.591.041**
Share Capital	1.866.584	1.661.338
Reserves	14.000.233	13.598.842
Profit for the year	(1.764.474)	(1.753.579)
Shareholder's equity (own funds)	**14.102.343**	**13.506.602**
Minority interest capital & reserves	**60.612**	**209.330**
Minority interest results	**-105.822**	**-77.191**
Total sources	**30.701.731**	**28.229.782**

Net working capital increased during the half-year under review, standing at €8.7 million as of 30 June 2025 compared to €6.2 million at 31 December 2024.

Trade receivables amounted to €21.2 million compared to €24.0 million as of 31 December 2024; trade payables amounted to €11.3 million at 30 June 2025 (€15.9 million at 31 December 2024).

Tax receivables and payables amounted to €-0.4 million (€-0.3 million at 31 December 2024).

The Group's net invested capital as of 30 June 2025 amounted to €30.7 million compared to €28.2 million, an increase of 9%.

Net financial debt amounted to €16.6 million as of 30 June 2025, compared to €14.6 million at 31 December 2024.

Shareholders' equity amounted to €14.1 million (€13.5 million as of 31 December 2024).

Capex for the first half of 2025 amounted to €0.6 million.

Net Debt

Net Financial Debt (Eur)	30.06.2025	31.12.2024
A. Liquidity	(2.492.859)	(3.241.289)
B. Cash Equivalents	-	-
C. Other current assets	(249.609)	(312.120)
D. Cash and cash equivalents (A) + (B) + (C)	-2.742.468	-3.553.409
E. Current financial debt	11.443.383	11.935.454
F. Current portion of non-current debt	3.694.935	2.071.746
G. Current financial debt (E)+(F)	15.138.319	14.007.200
H. Net current financial debt (G)-(D)	12.395.851	10.453.791
I. Non-current financial debt	4.248.747	4.137.251
J. Debt Instruments	-	-
K. Trade payables and other non-current payables	-	-
L. Non-current financial debt (I) + (J) + (K)	4.248.747	4.137.251
M. Total financial debt (H) + (L)	16.644.598	14.591.041

Current part of non-current financial debt increasing compared to 2024 due to new debt and short term bond restructuring.

Temporary deferral of trade payables reclassified within the net financial position

Outlook

All the sectors covered by the Group continue to demonstrate strong growth potential and solid profitability, with increasing opportunities for international expansion.

In 2025, the global geopolitical climate has further accelerated investments in the defense sector, reinforcing the strategic relevance of SolidWorld Group’s integrated solutions in this field.

The ongoing integration of the Group’s companies—designed to streamline operations and simplify the organizational structure—remains a key focus, involving both the parent company and its subsidiaries.

Looking ahead, the Group is committed to sustained investment in the development of cutting-edge software, hardware, and comprehensive support and training services, consolidating its role as a strategic partner across its core industrial, biomedical, and defense markets..

3. Strategic drivers and achievements

Strategic drivers in Industry 4.0/5.0

CONSOLIDATION OF THE COMPETITIVE POSITION

- Technological transition from **On Premise to In Cloud**
- Enhancement of **sales of own products Integr@ Software**
- Started collaborations in the **aerospace industry**
- **Launch** the **distribution** of 3D printers for decorations on fabrics and textiles

STREGHTENING OF THE POSITION IN 3D DESIGN AND SOFTWARE MARKET

- Acquisition of **Valore BF 3D (100%)**, newly established company which sells the SolidWorks 3D CAD software, developed by Dassault Systèmes SE, of which SolidWorld is also an authorized reseller in Italy.

Rationalization of the Group to exploit synergies

PROCESS OF SIMPLIFICATION OF THE GROUP STRUCTURE

- **Leverage** operating, commercial, administrative and corporate synergies by **restructuring** and **optimising** the decision-making levels and personnel and overhead cost management
- Incorporation of the subsidiary **SolidEngineering**
- other **mergers** or incorporations are being evaluated to achieve greater efficiency

Increase international presence of the businesses

CONSOLIDATED AND STRANGTHEN

SOLIDWORLD MIDDLE EAST IN DUBAI

- Targets the **Middle East market** to support local businesses in the technological process of product development offering **integrated solutions** especially in the **biomedical and defense sectors**.

Additional strategic pillar of development

DEFENSE

Strategic pillar for growth in high-demand markets

SolidWorld Group is playing a key role in the fast-growing defense sector in the Middle East, particularly in Saudi Arabia, where the government is investing heavily to diversify its economy and strengthen national security.

Thanks to advanced 3D printing technologies, SolidWorld is able to produce highly complex, customized military components with speed and flexibility — a crucial advantage in today's geopolitical climate.

The Group's engineering know-how and the excellence of Italian manufacturing are highly valued by institutional clients, positioning SolidWorld Group as a trusted partner for strategic defense projects.

The defense market in the Middle East and Africa is expected to grow significantly, reaching over $47 billion by 2030, driven by increased military spending and regional instability.

**Source: Grand View Research*

4. Annex

SolidWorld Group Shareholding

Shareholder	Multi-voting shares with the right of 3 voting	No. ordinary shares	Total No. of shares	% of Share Capital	No. of Voting Rights	% of Voting Rights	% of Listed Shares
Roberto Rizzo	**2.205.170**	**1.673.804**	**3.878.974**	**20,78%**	**8.289.314**	**32,50%**	**10,98%**
Through Prime S.r.l.	*2.205.170*	*1.636.679*	*3.841.849*	*20,58%*	*8.252.189*	*32,35%*	*10,73%*
As natural person	-	*37.125*	*37.125*	*0,20%*	*37.125*	*0,15%*	*0,24%*
Marco Calini	**1.214.670**	**974.158**	**2.188.828**	**11,73%**	**4.618.168**	**18,11%**	**6,39%**
Trhough AL.CA S.r.l.	*1.050.000*	*759.225*	*1.809.225*	*9,69%*	*3.909.225*	*15,33%*	*4,98%*
As natural person	*164.670*	*214.933*	*379.603*	*2,03%*	*708.943*	*2,78%*	*1,41%*
RedFish LongTerm Capital S.p.A.	**-**	**1.359.983**	**1.359.983**	**7,29%**	**1.359.983**	**5,33%**	**8,92%**
Market	**-**	**11.238.860**	**10.238,860**	**60,21%**	**11.238.860**	**44,06%**	**73,71%**
Total	**3.419.840**	**15.246.805**	**18.666.645**	**100,00%**	**25.506.325**	**100,00%**	**100,00%**

Industry 4.0/5.0 - Clients and collaborations

Extensive customer base with more than 8.000 clients and consolidated relationships with the top Italian Universities.

Client diversification is extremely high (low concentration with top 10 clients reaching less than 10% of revenues).

Client

LAMBORGHINI
MASERATI
DUCATI
FCA
brembo
MAGNETI MARELLI
LEONARDO
NATUZZI
IMA Sustain Ability
FAMECCANICA Non stop innovation
Poltrona Frau
ARISTON
CHANEL
Valcucine
Safilo GROUP
FAAC
ZUCCHETTI.
Artemide
BVLGARI

Collaboration with Top Universities

Università di Pisa
Università degli Studi di Milano
Politecnico Milano 1863
Università degli Studi Firenze
Università di Trento
Università degli Studi di Trieste
Università di Parma
Politecnico di Bari
Università di Verona
Università di Siena 1240
Università degli Studi di Padova
Alma Mater Studiorum Università di Bologna
L-Università ta' Malta

SolidWorld Group 2025 Key Facts

Jan

Signing of an important Memorandum of Understanding between its subsidiary Due Pi Greco Srl and a leading customer in the Middle East. The agreement provides for the supply of advanced solutions for the military sector, marking a strategic milestone in the internationalization and strong expansion of the Group in the defense sector.

Strengthen in the defense business, which is growing strongly worldwide. A decisive step made possible by the completion of its path towards the creation of an Italian hub of technological excellence that integrates advanced skills and cutting-edge technologies for the defense-aerospace sector.

Feb

Digital Biofabrication of Living Human Tissue presented on stage at 3DEXPERIENCE World 2025 in Houston. Electrospider, the Innovative 3D Bioprinter Revolutionizing Regenerative Medicine, introduced by Aurora De Acutis, President of Bio3DPrinting.

Mar

500,000 euro contract won in the aerospace & defense sector. Joined the venetian regional innovative network "Air - Aerospace, Innovation and reasearch".

SolidWorld Group
2025 Key Facts

Apr

Artificial Intelligence into design: from July 2025, complete integration in the first ai-centric CAD software platform. Computer-Aided Design (CAD) and Artificial Intelligence (AI) will be fully integrated and made available to a client base of over 10,000 medium and large manufacturing companies, enabling significant acceleration in design processes and the development of new product types.

May

With 3D Printing – Tech Day in Abu Dhabi, SolidWorld Group continues its international growth, aiming to strengthen its presence in high-potential regions requiring cutting-edge technologies in strategic industrial sectors such as energy and defense.

Jun

In June 2025, SolidWorld Group successfully completed its capital increase, reaching nearly 100% subscription of the offer through the placement of 384,450 shares with qualified investors. The operation strengthens the Group’s financial structure and supports future growth in the defense and biomedical sectors

SolidWorld Group 2025 Key Facts

Jul

With the opening of the new Due Pi Greco Technology Hub in Resana and the launch of its industrial plan, SolidWorld Group consolidates its leadership in additive manufacturing, integrating advanced CAD/CAM solutions and sustainable production systems. The month also marked the release of the Group's first Sustainability Report, reaffirming its long-term commitment to innovation, circular economy, and responsible growth.

Aug

With the exercise of 1,464 SolidWorld Group 2022–2025 Warrants, resulting in the issuance of 805 new ordinary shares, the Group further optimized its capital structure while maintaining a stable and transparent shareholder base, led by Chairman Roberto Rizzo and Vice Chairman Marco Calini.

Sep

With the ISO 13485 certification awarded to Bio3DModel, SolidWorld Group strengthens its position in the medical sector, confirming the company's reliability and commitment to the highest quality and safety standards in 3D printing for healthcare. The certification, granted by IMQ, marks a strategic milestone enabling participation in national tenders and expanding growth opportunities in biomedical innovation.

Disclaimer

The information contained in this presentation, which has been prepared by SolidWorld GROUP S.p.A. (the “Company”) and its consolidated subsidiaries (together, the “Group”) and it is under the responsibility of the Company, does not constitute or form part of any offer to sell or issue or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. The information and opinions contained in this document are provided as at the date of the presentation and are subject to change.

The Group expressly disclaims any duty, undertaking or obligation to update publicly or release any revisions to any of the information, opinions or forward-looking statements contained in this document to reflect any events or circumstances occurring after the date of the presentation of this document. No representation or warranty is made as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements. Any reference to past performance or trends or activities of the Company shall not be taken as a representation or indication that such performance, trend or activity will continue in the future.

This document may not be reproduced or distributed, in whole or in part, by any person other than the Company; by viewing and/or accepting a copy of this document, you agree to be bound by the foregoing limitations. Additional information on the factors that could have an impact on the Group financial results is contained in the documents filed by the Group and available on the Group’s website at www.solidworld.it.

SolidWorld
GROUP

The 3D Digital World

Thank you!